Weimin Li

Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study.

M. Rebelatto, J. W. Kim, P. Mccoon, 2022, The lancet. Gastroenterology & hepatology.

Plasma-based tumor mutational burden (bTMB) as predictor for survival in phase III EAGLE study: Durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum failure.

R. Ferris, L. Licitra, R. Haddad, 2020 .

Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti–Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer

H. Feilotter, D. Tu, H. Kennecke, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular biomarkers to identify patients (pts) who may benefit from durvalumab (D; anti-PD-L1) ± tremelimumab (T; anti-CTLA-4) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) from HAWK and CONDOR studies.

A. Matakidou, L. Siu, Z. Ghazoui, 2020 .

Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D) ± tremelimumab (T) and gemcitabine/cisplatin (GemCis) in chemo-naïve advanced biliary tract cancer (aBTC).

M. Rebelatto, J. W. Kim, D. Oh, 2020 .

Cost-effectiveness evaluation based on two models of first-line atezolizumab monotherapy and chemotherapy for advanced non-small cell lung cancer with high-PDL1 expression

P. Tian, Jing Tan, Chuan Zhang, 2023, Frontiers in Oncology.

Tissue and plasma tumor mutation burden (TMB) as predictive biomarkers in the CO.26 trial of durvalumab + tremelimumab (D+T) versus best supportive care (BSC) in metastatic colorectal cancer (mCRC).

H. Feilotter, D. Tu, H. Kennecke, 2021 .

Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

L. Siu, L. Licitra, R. Haddad, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.